High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

NCT00571584 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Haemophilia B With Inhibitors

Interventions

DRUG: activated recombinant human factor VII

Sponsor

Novo Nordisk A/S